Moreover, a study by Niu et al. revealed that cytarabine or daunorubicin combined with venetoclax treatment resulted in increased DNA damage and a better reduction in Mcl-1 levels in AML cell lines than during venetoclax monotherapy [121]. Here, MCL1 is linked to acute myeloid leukemia.